• EZ Cap EGFP mRNA: Cap 1 Reporter Workflow

  2026-10-01

  EZ Cap EGFP mRNA is a Cap 1 EGFP reporter mRNA input for evaluating delivery and transient expression in research systems. Its documented role is assay reporting, not treatment, and its supplied information does not establish a universal dose, cell type, delivery method, or readout window.

• GW4064: FXR Activation in Bile-Flow Research

  2026-10-01

  GW4064 is a non-steroidal FXR agonist for connecting receptor activation with bile acid transport, tight-junction integrity, and lipid phenotypes. This article translates recent cholestatic injury findings into practical assay decisions for mechanistic metabolic research.

• Reversible Epiblast Regionalization in Human PSCs

  2026-09-30

  A Nature Biotechnology study links human pluripotent stem cell differentiation bias to reversible anterior–posterior epiblast-like regionalization and locus-specific erosion of bivalent chromatin, rather than DNA methylation alone. Its chemical chromatin restoration strategy recovered anterior-like molecular features, neural organoid competence, and broader germ-layer differentiation, providing a framework for evaluating and rescuing compromised hPSC lines.

• GSK 2837808A: From LDHA to Immune Metabolism

  2026-09-30

  GSK 2837808A offers a precise way to interrogate LDHA-dependent lactate biology while opening a hypothesis-driven bridge to the NAT1–ENO1–lactate–PD-L1 axis described in colorectal cancer. This article connects biochemical potency, cellular metabolism, pharmacokinetic constraints, and translational study design without overstating preclinical evidence.

• Ceftolozane Sulfate: From MIC to Model

  2026-09-29

  Ceftolozane sulfate research requires more than a MIC value: target biology, resistance mechanism, and exposure must align. This guide develops an evidence-based framework for translating susceptibility data into interpretable PK/PD and infection-model decisions.

• ZCL278: Selective Cdc42 Inhibitor Guide

  2026-09-29

  ZCL278 is a selective Cdc42 inhibitor for mechanistic studies of cell motility, neuronal morphology, and Cdc42 signaling. Supplier-reported data define an 11.4 μM dissociation constant and cellular effects in cancer, neuronal, and fibroblast models, while separate kidney-fibrosis research supports Cdc42 as a disease-relevant target.

• Anlotinib hydrochloride: Angiogenesis Assay Workflows

  2026-09-28

  Anlotinib hydrochloride provides a mechanism-led way to connect VEGFR2, PDGFRβ, and FGFR1 inhibition with endothelial phenotypes. This practical guide shows how to design migration, tube formation, phosphorylation, and translational cancer research workflows while avoiding common assay artifacts.

• Anlotinib Hydrochloride: Angiogenesis Assay Guide

  2026-09-28

  Build a mechanism-led workflow with Anlotinib hydrochloride to test VEGFR2-centered signaling alongside PDGFRβ- and FGFR1-associated angiogenic responses. Practical assay guidance covers endothelial migration, tube formation, pathway readouts, and controls that help distinguish anti-angiogenic activity from nonspecific toxicity.

• 3-Methyladenine for ALOX5-Ferroptosis Studies

  2026-09-27

  Learn how 3-Methyladenine can help test whether autophagy contributes to ferroptosis escape in bladder cancer models. This article connects ALOX5-focused findings with careful assay design, controls, and interpretation limits.

• Sulfo-NHS-SS-Biotin: Read the Surface Signal

  2026-09-26

  Sulfo-NHS-SS-Biotin supports selective, cleavable labeling of accessible cell-surface proteins. Learn how to use it to enrich surface proteins while distinguishing biochemical capture from evidence of molecular organization.

• CHIR-99021 (CT99021): GSK-3 to Cell Fate

  2026-09-25

  CHIR-99021 is a useful experimental lever for probing how GSK-3 inhibition shapes stem-cell state and differentiation—but pathway activation is not the same as cell-fate control. This article connects its mechanistic value to new single-fibre evidence that chromatin accessibility is structurally diverse, then translates that perspective into practical, cautious guidance for reproducible experiments.

• MK-571 (L-660,711) Workflow for Inflammation Research

  2026-09-25

  Use MK-571 to separate cysteinyl-leukotriene receptor signaling from MRP1-related transport effects in airway and immune-cell experiments. This practical workflow covers assay selection, compound handling, controls, and the limits of translating transporter findings across models.

• D-Luciferin for Glioma Immune-Response Imaging

  2026-09-24

  D-Luciferin is a firefly luciferase substrate for reporter imaging, but its signal answers a different question from soluble PD-L1 measurements. This article explains how to combine bioluminescence readouts with glioma immunology without mistaking tumor burden, gene expression, or ATP-dependent signal for immune function.

• Sodium Phosphate Dibasic in Ecotoxicity Assays

  2026-09-24

  Sodium phosphate dibasic can support controlled pH in biochemical workflows, but aquatic toxicity tests demand careful attention to how buffer composition changes the exposure itself. This article connects Na2HPO4 chemistry with a multi-species sulfamonomethoxine study and offers practical checks for assay design.

• GW4064 Workflows for FXR and Bile Acid Research

  2026-09-23

  Use GW4064 to probe FXR activation alongside bile acid efflux and hepatocyte barrier readouts in cholestatic-injury models. This workflow connects a recent oleanolic-acid study to practical assay design while clearly separating published findings from proposed GW4064 experiments.

8288 records 1/553 page Next 12345 下5页 Last page